Medigen Vaccine Biologics (TWO:6547) — Market Cap & Net Worth
Market Cap & Net Worth: Medigen Vaccine Biologics (6547)
Medigen Vaccine Biologics (TWO:6547) has a market capitalization of $534.44 Million (NT$16.96 Billion) as of August 11, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #11879 globally and #427 in its home market, demonstrating a 13.16% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medigen Vaccine Biologics's stock price NT$51.60 by its total outstanding shares 328749000 (328.75 Million). See 6547 capital expenditure intensity to understand how much of operating cash flow is reinvested back into capital assets.
Medigen Vaccine Biologics Market Cap History: 2015 to 2026
Medigen Vaccine Biologics's market capitalization history from 2015 to 2026. Data shows growth from $216.82 Million to $534.44 Million (10.67% CAGR).
Medigen Vaccine Biologics Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medigen Vaccine Biologics's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.64x
Medigen Vaccine Biologics's market cap is 0.64 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $194.30 Million | $1.12 Million | -$636.84 Million | 173.48x | N/A |
| 2020 | $716.84 Million | $11.51 Million | -$690.70 Million | 62.30x | N/A |
| 2021 | $2.08 Billion | $3.28 Billion | $1.41 Billion | 0.63x | 1.48x |
| 2022 | $719.84 Million | $365.04 Million | -$1.50 Billion | 1.97x | N/A |
| 2023 | $726.05 Million | $389.62 Million | -$1.16 Billion | 1.86x | N/A |
| 2024 | $373.38 Million | $605.64 Million | -$80.47 Million | 0.62x | N/A |
| 2025 | $390.99 Million | $613.17 Million | -$281.71 Million | 0.64x | N/A |
Competitor Companies of 6547 by Market Capitalization
Companies near Medigen Vaccine Biologics in the global market cap rankings as of August 11, 2026.
Key companies related to Medigen Vaccine Biologics by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #223 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #428 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #547 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- Samsung Biologics Co Ltd (KO:207940): Ranked #555 globally with a market cap of $48.81 Billion USD ( ₩72.03 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #223 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $496.07 |
| #428 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $784.36 |
| #547 | Argen-X | BR:ARGX | $49.55 Billion | €763.20 |
| #555 | Samsung Biologics Co Ltd | KO:207940 | $48.81 Billion | ₩1556000.00 |
Medigen Vaccine Biologics Historical Marketcap From 2015 to 2026
Between 2015 and today, Medigen Vaccine Biologics's market cap moved from $216.82 Million to $ 534.44 Million, with a yearly change of 10.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$534.44 Million | +36.69% |
| 2025 | NT$390.99 Million | +4.72% |
| 2024 | NT$373.38 Million | -48.57% |
| 2023 | NT$726.05 Million | +0.86% |
| 2022 | NT$719.84 Million | -65.41% |
| 2021 | NT$2.08 Billion | +190.29% |
| 2020 | NT$716.84 Million | +268.94% |
| 2019 | NT$194.30 Million | -17.88% |
| 2018 | NT$236.60 Million | +29.25% |
| 2017 | NT$183.06 Million | -10.79% |
| 2016 | NT$205.20 Million | -5.36% |
| 2015 | NT$216.82 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 10th, 2026 the market cap of Medigen Vaccine Biologics was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $534.44 Million USD |
| MoneyControl | $534.44 Million USD |
| MarketWatch | $534.44 Million USD |
| marketcap.company | $534.44 Million USD |
| Reuters | $534.44 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Medigen Vaccine Biologics
Medigen Vaccine Biologics Corporation, a biotechnology drug company, engages in the research, development, and wholesale of vaccines and biopharmaceuticals, and medical devices in Taiwan. It develops enterovirus A71 vaccine, which is in Phase III clinical trial to treat enterovirus infection with severe complications; and Quadrivalent influenza vaccine, which is in Phase III clinical trial for th… Read more